RAPGEF3 and cardiac hypertrophy: Consistent with the genetic data, pharmacological inhibition of Epac1, by the Epac1-selective inhibitor AM-001, ameliorated contractility and attenuated cardiac hypertrophy, inflammation induced by chronic β-AR stimulation with isoprenaline in C57BL/6 mice [45].